

## Allegato

Curriculum vitae di Elena Gagliardini

### PUBBLICAZIONI

**The Role of Angiotensin II in Parietal Epithelial Cell Proliferation and Crescent Formation in Glomerular Diseases.** Rizzo P, Novelli R, Rota C, Gagliardini E, Ruggiero B, Rottoli D, Benigni A, Remuzzi G. *Am J Pathol* 2017 Nov;187(11):2441-2450.

**Another Piece of the Puzzle of Podocyte B7-1 Expression: Lupus Nephritis.** Novelli R, Gagliardini E, Ruggiero B, Benigni A, Remuzzi G. *Nephron*. 2016 May 21.

**Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?** Novelli R, Gagliardini E, Ruggiero B, Benigni A, Remuzzi G. *Am J Physiol Renal Physiol*. 2016 Mar 1;310(5):F335-41

**B7-1 Is Not Induced in Podocytes of Human and Experimental Diabetic Nephropathy.** Gagliardini E, Novelli R, Corna D, Zoja C, Ruggiero B, Benigni A, Remuzzi G. *J Am Soc Nephrol*. 2015 Aug 28.

**Mitochondrial-dependent Autoimmunity in Membranous Nephropathy of IgG4-related Disease.** Buelli S, Perico L, Galbusera M, Abbate M, Morigi M, Novelli R, Gagliardini E, Tentori C, Rottoli D, Sabadini E, Saito T, Kawano M, Saeki T, Zoja C, Remuzzi G, Benigni A. *EBioMedicine*. 2015 Mar 6;2(5):456-66.

**Regression of Renal Disease by Angiotensin II Antagonism Is Caused by Regeneration of Kidney Vasculature.** Remuzzi A, Sangalli F, Macconi D, Tomasoni S, Cattaneo I, Rizzo P, Bonandrini B, Bresciani E, Longaretti L, Gagliardini E, Conti S, Benigni A, Remuzzi G. *J Am Soc Nephrol*. 2015 Jun 26.

**ET and diabetic nephropathy: preclinical and clinical studies.** Gagliardini E, Zoja C, Benigni A. *Semin Nephrol*. 2015 Mar;35(2):188-96.

**Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.** Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pellé T, Gaspari F, Suardi F, Gagliardini E, Orisio S, Benigni A, Ronco P, Remuzzi G. *J Am Soc Nephrol*. 2015 Oct;26(10):2545-58.

**Drugs to foster kidney regeneration in experimental animals and humans.** Gagliardini E, Benigni A. *Nephron Exp Nephrol*. 2014;126(2):91.

**An unanticipated role for survivin in organ transplant damage.** Cassis P, Solini S, Azzollini N, Aiello S, Rocchetta F, Conti S, Novelli R, Gagliardini E, Mister M, Rapezzi F, Rapezzi S, Benigni A, Remuzzi G, Conway EM, Noris M. *Am J Transplant*. 2014 May;14(5):1046-60.

**Abatacept in B7-1-positive proteinuric kidney disease.** Benigni A, Gagliardini E, Remuzzi G. *N Engl J Med*. 2014 Mar 27;370(13):1261-3

**$\beta$ -arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury.** Buelli S, Rosanò L, Gagliardini E, Corna D, Longaretti L, Pezzotta A, Perico L, Conti S, Rizzo P, Novelli R, Morigi M, Zoja C, Remuzzi G, Bagnato A, Benigni A. *J Am Soc Nephrol*. 2014 Mar;25(3):523-33.

**Nature and mediators of parietal epithelial cell activation in glomerulonephritides of human and rat.** Rizzo P, Perico N, Gagliardini E, Novelli R, Alison MR, Remuzzi G, Benigni A. *Am J Pathol*. 2013 Dec;183(6):1769-78.

**Angiotensin II contributes to diabetic renal dysfunction in rodents and humans via Notch1/Snail pathway.** Gagliardini E, Perico N, Rizzo P, Buelli S, Longaretti L, Perico L, Tomasoni S, Zoja C, Macconi D, Morigi M, Remuzzi G, Benigni A. *Am J Pathol*. 2013 Jul;183(1):119-30.

**Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy.** Zoja C, Garcia PB, Rota C, Conti S, Gagliardini E, Corna D, Zanchi C, Bigini P, Benigni A, Remuzzi G, Morigi M. *Am J Physiol Renal Physiol*. 2012 Nov 1;303(9):F1370-81.

**A novel strategy to enhance mesenchymal stem cell migration capacity and promote tissue repair in an injury specific fashion.** Xinaris C, Morigi M, Benedetti V, Imberti B, Fabricio AS, Squarcina E, Benigni A, Gagliardini E, Remuzzi G. *Cell Transplant*. 2013;22(3):423-36.

**Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury.** Cassis P, Gallon L, Benigni A, Mister M, Pezzotta A, Solini S, Gagliardini E, Cugini D, Abbate M, Aiello S, Rocchetta F, Scudeletti P, Perico N, Noris M, Remuzzi G. *Kidney Int*. 2012 May;81(9):903-18.

**Human amniotic fluid stem cell preconditioning improves their regenerative potential.** Rota C, Imberti B, Pozzobon M, Piccoli M, De Coppi P, Atala A, Gagliardini E, Xinaris C, Benedetti V, Fabricio AS, Squarcina E, Abbate M, Benigni A, Remuzzi G, Morigi M. *Stem Cells Dev*. 2012 Jul 20;21(11):1911-23.

**Endothelin in chronic proteinuric kidney disease.** Gagliardini E, Buelli S, Benigni A. *Contrib Nephrol*. 2011;172:171-84.

**Inhibiting angiotensin-converting enzyme promotes renal repair by limiting progenitor cell proliferation and restoring the glomerular architecture.** Benigni A, Morigi M, Rizzo P, Gagliardini E, Rota C, Abbate M, Ghezzi S, Remuzzi A, Remuzzi G. *Am J Pathol.* 2011 Aug;179(2):628-38.

**Both darbepoetin alfa and carbamylated erythropoietin prevent kidney graft dysfunction due to ischemia/reperfusion in rats.** Cassis P, Azzollini N, Solini S, Mister M, Aiello S, Cugini D, Scudeletti P, Gagliardini E, Abbate M, Gallon L, Remuzzi G, Noris M. *Transplantation.* 2011 Aug 15;92(3):271-9.

**Membranous nephropathy associated with IgG4-related disease.** Cravedi P, Abbate M, Gagliardini E, Galbusera M, Buelli S, Sabadini E, Marasà M, Beck LH Jr, Salant DJ, Benigni A, D'Agati V, Remuzzi G. *Am J Kidney Dis.* 2011 Aug;58(2):272-5.

**Rabbit anti-rat thymocyte immunoglobulin preserves renal function during ischemia/reperfusion injury in rat kidney transplantation.** Aiello S, Cassis P, Mister M, Solini S, Rocchetta F, Abbate M, Gagliardini E, Benigni A, Remuzzi G, Noris M. *Transpl Int.* 2011 Aug;24(8):829-38.

**Imaging of the porous ultrastructure of the glomerular epithelial filtration slit.** Gagliardini E, Conti S, Benigni A, Remuzzi G, Remuzzi A. *J Am Soc Nephrol.* 2010 Dec;21(12):2081-9

**Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.** Zoja C, Corna D, Gagliardini E, Conti S, Arnaboldi L, Benigni A, Remuzzi G. *Am J Physiol Renal Physiol.* 2010 Nov;299(5):F1203-11

**Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes.** Gagliardini E, Corna D, Zoja C, Sangalli F, Carrara F, Rossi M, Conti S, Rottoli D, Longaretti L, Remuzzi A, Remuzzi G, Benigni A. *Am J Physiol Renal Physiol.* 2009 Aug 12.

**Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition.** Macconi D, Sangalli F, Bonomelli M, Conti S, Condorelli L, Gagliardini E, Remuzzi G, Remuzzi A. *Am J Pathol.* 2009 Mar;174(3):797-807.

**Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides.** Macconi D, Chiabrando C, Schiarea S, Aiello S, Cassis L, Gagliardini E, Noris M, Buelli S, Zoja C, Corna D, Mele C, Fanelli R, Remuzzi G, Benigni A. *J Am Soc Nephrol.* 2009 Jan;20(1):123-30.

**Propionyl-L-carnitine prevents early graft dysfunction in allogeneic rat kidney transplantation.** Azzollini N, Cugini D, Cassis P, Pezzotta A, Gagliardini E, Abbate M, Arduini A, Peschechera A, Remuzzi G, Noris M. *Kidney Int.* 2008 Dec;74(11):1420-8.

**Effects of Rituximab on Morphofunctional Abnormalities of Membranous Glomerulopathy.** Ruggenenti P, Cravedi P, Sghirlanzoni MC, Gagliardini E, Conti S, Gaspari F, Marchetti G, Abbate M, Remuzzi G. *Clin J Am Soc Nephrol.* 2008 Aug

**Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury.** Ruggenenti P, Perico N, Gotti E, Cravedi P, D'Agati V, Gagliardini E, Abbate M, Gaspari F, Cattaneo

D, Noris M, Casiraghi F, Todeschini M, Cugini D, Conti S, Remuzzi G. *Transplantation*. 2007 Oct 27;84(8):956-64.

**Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (Campath-1H).** Gallon L, Gagliardini E, Benigni A, Kaufman D, Waheed A, Noris M, Remuzzi G. *Clin J Am Soc Nephrol*. 2006 May;1(3):539-45.

**Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus.** Benigni A, Caroli C, Longaretti L, Gagliardini E, Zoja C, Galbusera M, Moioli D, Romagnani P, Tincani A, Andreoli L, Remuzzi G. *Arthritis Rheum*. 2007 May;56(5):1569-78.

**Therapeutic potential of TGF-beta inhibition in chronic renal failure.** Gagliardini E, Benigni A. *Expert Opin Biol Ther*. 2007 Mar;7(3):293-304. Review

**Beneficial effect of TGFbeta antagonism in treating diabetic nephropathy depends on when treatment is started.** Benigni A, Zoja C, Campana M, Corna D, Sangalli F, Rottoli D, Gagliardini E, Conti S, Ledbetter S, Remuzzi G. *Nephron Exp Nephrol*. 2006;104(4):e158-68

**Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone.** Benigni A, Zoja C, Tomasoni S, Campana M, Corna D, Zanchi C, Gagliardini E, Garofano E, Rottoli D, Ito T, Remuzzi G. *J Am Soc Nephrol*. 2006 Jun;17(6):1624-32

**ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease.** Remuzzi A, Gagliardini E, Sangalli F, Bonomelli M, Piccinelli M, Benigni A, Remuzzi G. *Kidney Int*. 2006 Apr;69(7):1124-1130.

**Role of anti-TGF-beta antibodies in the treatment of renal injury.** Gagliardini E, Benigni A. *Cytokine Growth Factor Rev*. 2006 Feb-Apr;17(1-2):89-96.

**Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with Campath-1H induction therapy.** Hill P, Gagliardini E, Ruggenenti P, Remuzzi G. *Nephrol Dial Transplant*. 2005 Aug;20(8):1741-4.

**Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion.** Cugini D, Azzollini N, Gagliardini E, Cassis P, Bertini R, Colotta F, Noris M, Remuzzi G, Benigni A. *Kidney Int*. 2005 May;67(5):1753-61.

**Targeted deletion of angiotensin II type 1A receptor does not protect mice from progressive nephropathy of overload proteinuria.** Benigni A, Corna D, Zoja C, Longaretti L, Gagliardini E, Perico N, Coffman TM, Remuzzi G. *J Am Soc Nephrol*. 2004 Oct;15(10):2666-74.

**Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy.** Benigni A, Gagliardini E, Tomasoni S, Abbate M, Ruggenenti P, Kalluri R, Remuzzi G. *Kidney Int*. 2004 Jun;65(6):2193-200.

**Favorable effect of cotransfection with TGF-beta and CTLA4Ig of the donor kidney on allograft survival.** Tomasoni S, Longaretti L, Azzollini N, Gagliardini E, Mister M, Buehler T, Remuzzi G, Benigni A. *Am J Nephrol*. 2004 May-Jun;24(3):275-83.

**Changes in glomerular perm-selectivity induced by angiotensin II imply podocyte dysfunction and slit diaphragm protein rearrangement.** Benigni A, Gagliardini E, Remuzzi G. *Semin Nephrol.* 2004 Mar;24(2):131-40. Review.

**ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established.** Noris M, Mister M, Pezzotta A, Azzollini N, Cassis P, Benigni A, Gagliardini E, Perico N, Remuzzi G. *Kidney Int.* 2003 Dec;64(6):2253-61.

**Targeted downregulation of extracellular nephrin in human IgA nephropathy** Gagliardini E, Benigni A, Tomasoni S, Abbate M, Kalluri R, Remuzzi G. *Am J Nephrol.* 2003 Jul-Aug;23(4):277-86.

**Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat.** Benigni A, Zoja C, Corna D, Zatelli C, Conti S, Campana M, Gagliardini E, Rottoli D, Zanchi C, Abbate M, Ledbetter S, Remuzzi G. *J Am Soc Nephrol.* 2003 Jul;14(7):1816-24.

**Effect of angiotensin II antagonism on the regression of kidney disease in the rat.** Remuzzi A, Gagliardini E, Donadoni C, Fassi A, Sangalli F, Lepre MS, Remuzzi G, Benigni A. *Kidney Int.* 2002 Sep;62(3):885-94.

**Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion.** Mister M, Noris M, Szymczuk J, Azzollini N, Aiello S, Abbate M, Trochimowicz L, Gagliardini E, Arduini A, Perico N, Remuzzi G. *Kidney Int.* 2002 Mar;61(3):1064-78.

**Angiotensin-converting enzyme inhibition prevents glomerular-tubule disconnection and atrophy in passive Heymann nephritis, an effect not observed with a calcium antagonist.** Benigni A, Gagliardini E, Remuzzi A, Corna D, Remuzzi G. *Am J Pathol.* 2001 Nov;159(5):1743-50.

**Combined treatment with mycophenolate mofetil and an angiotensin II receptor antagonist fully protects from chronic rejection in a rat model of renal allograft.** Noris M, Azzollini N, Pezzotta A, Mister M, Benigni A, Marchetti G, Gagliardini E, Perico N, Remuzzi G. *J Am Soc Nephrol.* 2001 Sep;12(9):1937-46.

**Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis.** Benigni A, Tomasoni S, Gagliardini E, Zoja C, Grunkemeyer JA, Kalluri R, Remuzzi G. *J Am Soc Nephrol.* 2001 May;12(5):941-8.

**Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals.** Remuzzi G, Zoja C, Gagliardini E, Corna D, Abbate M, Benigni A. *J Am Soc Nephrol.* 1999 Jul;10(7):1542-9.

## CAPITOLI

**“Endothelin in Chronic Proteinuric Kidney Disease”** Elena Gagliardini, Simona Buelli and Ariela Benigni in ‘Endothelins and Endothelin Receptors in Renal Physiology and Kidney Disease’ Editor: Matthias Barton (Zurich, Switzerland), Donald E. Kohan (Salt Lake City, USA)

**“Role of Transforming Growth Factor-beta in the Kidney: Physiology and Pathology”**. Elena Gagliardini and Ariela Benigni, in *Transforming Growth Factor-Beta in Cancer Therapy, Volume II Cancer Treatment and Therapy*  
Sonia B. Jakowlew, Ph.D., Editor  
The Humana Press, Inc., Publisher

**“Malattie renali progressive”**. Elena Gagliardini in *Antagonisti Recettoriali dell’endotelina quali composti e quali patologie*.  
Il Pensiero Scientifico Editore